AU2012211989B2 - Methods for treating brain injury - Google Patents

Methods for treating brain injury Download PDF

Info

Publication number
AU2012211989B2
AU2012211989B2 AU2012211989A AU2012211989A AU2012211989B2 AU 2012211989 B2 AU2012211989 B2 AU 2012211989B2 AU 2012211989 A AU2012211989 A AU 2012211989A AU 2012211989 A AU2012211989 A AU 2012211989A AU 2012211989 B2 AU2012211989 B2 AU 2012211989B2
Authority
AU
Australia
Prior art keywords
noise
exposure
nac
tinnitus
blast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012211989A
Other languages
English (en)
Other versions
AU2012211989A1 (en
Inventor
Robert A. Floyd
Richard D. Kopke
Rheal TOWNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Hough Ear Institute
Original Assignee
Oklahoma Medical Research Foundation
Hough Ear Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Hough Ear Institute filed Critical Oklahoma Medical Research Foundation
Publication of AU2012211989A1 publication Critical patent/AU2012211989A1/en
Application granted granted Critical
Publication of AU2012211989B2 publication Critical patent/AU2012211989B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012211989A 2011-02-04 2012-02-03 Methods for treating brain injury Active AU2012211989B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161439671P 2011-02-04 2011-02-04
US61/439,671 2011-02-04
PCT/US2012/023855 WO2012106654A1 (en) 2011-02-04 2012-02-03 Methods for treating brain injury

Publications (2)

Publication Number Publication Date
AU2012211989A1 AU2012211989A1 (en) 2013-08-22
AU2012211989B2 true AU2012211989B2 (en) 2017-03-02

Family

ID=46603106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012211989A Active AU2012211989B2 (en) 2011-02-04 2012-02-03 Methods for treating brain injury

Country Status (8)

Country Link
US (4) US9289404B2 (enExample)
EP (1) EP2670403B1 (enExample)
JP (2) JP6099574B2 (enExample)
AU (1) AU2012211989B2 (enExample)
CA (1) CA2826602C (enExample)
ES (1) ES2893825T3 (enExample)
IL (2) IL227768A (enExample)
WO (1) WO2012106654A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050305B2 (en) 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
WO2014172583A2 (en) * 2013-04-18 2014-10-23 Jinsheng Zhang Compositions and methods utilizing phosphodiesterase inhibitors to treat blast-induced tinnitus and/or hearing loss
WO2017048778A1 (en) * 2015-09-18 2017-03-23 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
SMT202400469T1 (it) 2016-05-18 2025-01-14 Sound Pharmaceuticals Incorporated Ebselen per l'uso nel trattamento della malattia di ménière
US10576125B2 (en) * 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
US20190046486A1 (en) * 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury
CN111132672A (zh) 2017-09-20 2020-05-08 俄克拉荷马医学研究基金会 抗药性胶质瘤的治疗
EP3700525A4 (en) 2017-10-27 2021-08-25 Beyond Barriers Therapeutics, Inc. IMPROVED PROVISION OF ANTIOXIDANTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES WITH OXIDATIVE STRESS
WO2019213245A1 (en) * 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
US20210369147A1 (en) * 2018-07-18 2021-12-02 The Regents Of The University Of California Multimodal Neuroimaging-Based Diagnostic Systems and Methods for Detecting Tinnitus
WO2020023755A1 (en) 2018-07-26 2020-01-30 CHS Pharma Inc. Treatment for ischemic stroke
EP3849530A4 (en) * 2018-09-12 2022-06-22 Hough Ear Institute METHODS OF TREATMENT OF HEARING LOSS AFTER COCHLEAR IMPLANT SURGERY
WO2026039548A1 (en) * 2024-08-13 2026-02-19 Mcleay Matthew Perfluorocarbon compositions, systems, and methods for ischemic, inflammatory, infectious, transplant, and other medical conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780510A (en) * 1993-12-23 1998-07-14 Oklahoma Medical Research Foundation 2,4-disulfo phenyl butyl nitrone, its salts and their use as pharmaceuticals
WO2001089507A1 (en) * 2000-05-23 2001-11-29 Astrazeneca Ab NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
WO2004034999A2 (en) * 2002-10-15 2004-04-29 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
WO2008013866A2 (en) * 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027376A2 (de) * 1998-10-26 2000-05-18 Michael Schedler Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
US6428474B1 (en) 2000-05-24 2002-08-06 Sol Weiss Surgical instrument
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CA2606053A1 (en) 2005-04-21 2006-11-02 Glenn Goldstein N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
US8231629B2 (en) 2006-06-29 2012-07-31 L.R.S. Ortho Ltd. System and method for locating of distal holes of an intramedullary nail
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US9289462B2 (en) 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780510A (en) * 1993-12-23 1998-07-14 Oklahoma Medical Research Foundation 2,4-disulfo phenyl butyl nitrone, its salts and their use as pharmaceuticals
WO2001089507A1 (en) * 2000-05-23 2001-11-29 Astrazeneca Ab NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
WO2004034999A2 (en) * 2002-10-15 2004-04-29 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
WO2008013866A2 (en) * 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma

Also Published As

Publication number Publication date
IL227768A0 (en) 2013-09-30
JP2017137321A (ja) 2017-08-10
US20140187631A1 (en) 2014-07-03
US9289404B2 (en) 2016-03-22
IL247911B (en) 2021-05-31
US10111843B2 (en) 2018-10-30
JP6286589B2 (ja) 2018-02-28
JP2014511374A (ja) 2014-05-15
ES2893825T3 (es) 2022-02-10
WO2012106654A1 (en) 2012-08-09
EP2670403A4 (en) 2014-07-09
JP6099574B2 (ja) 2017-03-22
US10022346B2 (en) 2018-07-17
US9642823B2 (en) 2017-05-09
AU2012211989A1 (en) 2013-08-22
CA2826602C (en) 2019-06-11
CA2826602A1 (en) 2012-08-09
US20170202797A1 (en) 2017-07-20
EP2670403A1 (en) 2013-12-11
US20170281583A1 (en) 2017-10-05
EP2670403B1 (en) 2021-08-18
IL247911A0 (en) 2016-11-30
US20160158173A1 (en) 2016-06-09
IL227768A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
US10022346B2 (en) Methods for treating brain injury
EP1562566B1 (en) Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride
Nakagami et al. 3-Hydroxykynurenine toxicity on the rat striatum in vivo
CN102256596B (zh) 用于增强对流递送到中枢神经中心的脂质体组合物
AU2004298393A1 (en) Copper antagonist compounds
KR20180098695A (ko) 지방 감소를 위한 담즙산 및 염의 방법 및 조성물
JP7003045B2 (ja) 神経変性の治療のための方法及び医薬組成物
Elkomy et al. Intranasal trimethyl chitosan-coated emulsomes containing tizanidine as brain-targeted therapy in spasticity: formulation, optimization, and pharmacokinetic assessment
EP3340972A1 (en) Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
US20090263507A1 (en) Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
Fan et al. The effect of thymoquinone on the characteristics of the brain extracellular space in transient middle cerebral artery occlusion rats
Fan et al. Delivering the acetylcholine neurotransmitter by nanodrugs as an effective treatment for Alzheimer's disease
CA3077036A1 (en) Compositions and methods for treating septic cardiomyopathy
RU2777871C1 (ru) Способ лечения нейродегенеративных заболеваний
Bartnik et al. Cell-permeant calcium buffer induced neuroprotection after cortical devascularization
US20230132378A9 (en) Compositions and methods for treating hemorrhagic stroke
EP1471901B1 (en) Spermidine derivative for the treatment of chronic neurodegenerative diseases
Deidda Retinal neurodegeneration and an innovative nanostructured approach in an iron overload in vivo model
WO2024059829A1 (en) Compositions and methods for protecting salivary glands from off-target radiation damage
WO2025231430A1 (en) Compositions and methods for localized adipocyte cell death
WO2017042314A1 (en) Methods and pharmaceutical composition for the treatment of post-traumatic epilepsies
Lin et al. Neuroprotection of Kynurenic Acid-Loaded Micelles for in Vitro and in Vivo Parkinson's Disease Models
HK40012341A (en) Methods for enhancing synaptogenesis and neuritogenesis
AU2015213386A1 (en) Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
HK1261266A1 (en) Method and pharmaceutical composition for treatment of neurodegeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)